Advanced searches left 3/3

Liver Disease - Europe PMC

Summarized by Plex Scholar
Last Updated: 20 April 2022

* If you want to update the article please login/register

Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK.

Context is a page that contains information about Context Ellagic acid is used in traditional medicine to treat hyperlipidaemia in diabetic patients. Rats had to experience Type 1 diabetes mellitus caused by AMPK's anti-steatotic activity of ellagic acid in streptozotocin-induced type 1 diabetes mellitus. EA + EA, T1DM + EA, T1DM + EA, and T1DM + EA + CC were divided into six groups as control, oversight + EA, control + EA, and control + EA. It also reduced hepatic levels of ROS 62%, MDA 52%, TNF-62 percent, and IL-6 57. 2%, as well as the nuclear presence of NF-62 54% but higher the nuclear presence of Nrf-2 4-fold and SOD 87%. Discussion and conclusions These results support the use of EA to treat hepatic disorders and non-alcoholic fatty liver disease NAFLD.

Source link: https://europepmc.org/article/MED/34870551


Serpina3c deficiency induced necroptosis promotes non-alcoholic fatty liver disease through β-catenin/Foxo1/TLR4 signaling.

Non-alcoholic fatty liver disease is a public health issue and a common cause of chronic liver disease worldwide. In vitro cell models induced by palmitic acid treatment were used to determine serpina3c's beneficial effect on necroptosis and the underlying molecular mechanism. DKO mice exhibited a significantly increased incidence of hepatic steatosis, elevated hepatic triglyceride content, and expression of genes involved in lipid metabolism, promoted hepatic inflammation and fibrosis, and promoted necroptosis by increasing the expression of receptor-interacting protein 3, phosphorylated mixed lineage kinase domain-like, and high mobility group box 1 compared to Apoe /- Foxo1 and -catenin colocalized in the nucleus under threat of lipotoxicity, triggering the expression of TLR4 in the nucleus, and Mechanistically, downregulation of serpina3c expression promoted TLR4 and -catenin. In vitro, the disruption of Foxo1-/catenin by Foxo1 and -catenin inhibitors reduced TLR4 expression and reduced hepatic necroptosis.

Source link: https://europepmc.org/article/MED/35429042


Behaviour Regulation, Locus of Control and the Role of Mental Health in Non-alcoholic Fatty Liver Disease

Background and Aims: Non-alcoholic fatty liver disease is the most common chronic liver disease in wealthy societies, and if left untreated, can be life-threatening. Results: 96 participants were divided into three groups, NAFLD patients, non-lifestyle liver disease patients, and healthy controls, and healthy controls were divided into three groups, reporting: 96 participants, who were divided into three groups, NAFLD patients, non-lifestyle liver disease patients, and healthy controls were analyzed, and a Tukey post-hoc analysis was performed. An association of personality disorders and NAFLD has been established. Conclusion: It is believed that NAFLD patients are screened for personality disorders and, if identified, treated prior to the start of diet and exercise control.

Source link: https://europepmc.org/article/PPR/PPR483278


Ammonium quantification (AQua) in human plasma by 1 H-NMR for staging of liver fibrosis in alcohol-related liver disease and non-alcoholic fatty liver disease.

Patients with chronic liver disease have a chronic liver disease prognosis, and liver fibrosis staging is a significant factor. Currently, biopsy is the only method capable of diagnosing liver fibrosis in patients with alcohol-related liver disease and non-alcoholic fatty liver disease unequivocally. We present 1 H nuclear magnetic resonance as a way to quickly determine ammonium ions from human plasma extracts and demonstrate their ability to investigate early and advanced stages of ArLD and NAFLD.

Source link: https://europepmc.org/article/MED/35435283


Association of Thyroid Autoimmunity with Nonalcoholic Fatty Liver Disease in Euthyroid Middle-aged Subjects: A Population-Based Study.

Objectives The relationship between thyroid autoimmunity and nonalcoholic fatty liver disease is not clear. In this research, we wanted to investigate the connection between thyroid autoimmunity and NAFLD in a large population of euthyroid patients. TPOAb was shown with a higher rate of optimism for TPOAb in comparison to those without NAFLD. Even after adjusting for confounding variables, including age, sex, household income, education, smoking, alcohol intake, walking habits, elevated blood pressure, and hyperglycemia, TPOAb positivity was a significant risk factor for NAFLD [OR 1. 668, 95% confidence interval 1. 019-2. 630, p=0. 042] after adjusting for confounding variables, including age, gender, household income, education, alcohol use, increased blood pressure, dyslipida, hypogly TPOAb positivity in addition determined the risk of advanced liver fibrosis in patients with NAFLD was determined by independent of the confounding conditions. Conclusion In euthyroid patients, thyroid autoimmunity is associated with NAFLD and advanced liver fibrosis, regardless of known cardiovascular risk factors.

Source link: https://europepmc.org/article/MED/35434848


Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH).

Nonalcoholic fatty liver disease, a medical disorder that ranges from nonalcoholic fatty liver to nonalcoholic steatohepatitis, is quickly evolving into a global pandemic. Patients in NAFLD are burdened with high incidences of metabolic syndrome-related comorbidities resulting in polypharmacy. Despite extensive clinical pharmacokinetic studies in cirrhosis, current knowledge of pharmacokinetic alterations in NAFLD, especially at various stages of disease progression, is rather limited. When it can be attributed to pharmacodynamic effects, the use of IVIVE-PBPK to forecast intra-organ drug concentrations at medically relevant sites of action is particularly useful. Quantitative methods pharmacology/toxicology modeling can be used to convert pharmacokinetic and pharmacodynamic data from PBPK/PD models into clinically useful predictions of drug response and toxicity. The application of literature-derived physiological parameters and ADME-associated protein abundance data to inform virtual NAFLD population growth and improve QSP/PD, QSP, and QST estimates is discussed, as well as current limitations and knowledge gaps.

Source link: https://europepmc.org/article/MED/35429164


Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes.

History The triglyceride glucose index as well as body mass index is a new index that measures insulin resistance in conjunction with body mass index. We wanted to investigate the predictive value of the triglyceride glucose-body mass index in relation to the occurrence of non-alcoholic fatty liver disease in the Chinese population with type 2 diabetes in this cross-sectional study. Methods We selected 826 patients with T2D who were hospitalized at the Department of Endocrinology and Metabolism of Karamay People's Hospital from September 2016 to October 2018 for this study. The liver tissue and liver were seen brighter than the renal cortex on ultrasound, suggesting that they were not NAFLD in the liver ultrasound. With a diagnosis of NAFLD, a logistic regression analysis was conducted to determine correlations between the triglyceride glucose index, TyG-BMI index, insulin resistance index, and the ratio of the triglycerides to high-density lipoprotein-cholesterol.

Source link: https://europepmc.org/article/MED/35428219


The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas.

Non-alcoholic fatty liver disease affects 20-25% of the general population and is linked to morbidity, increased mortality, and increased health-care costs. Most NAFLD risk factors are modifiable, and, as a result, can be reduced by public health policies, and thus, are potentially vulnerable to being reduced by public health initiatives. There are no details about NAFLD-related public health services in the Americas to date. We analyzed results from 17 American countries to see that none had developed national health services to reduce NAFLD-related deaths in this research. To reduce the burden of NAFLD in the Americas, the introduction of public health policies is urgently needed.

Source link: https://europepmc.org/article/MED/35430032


Pterostilbene and Its Derivative 3'-Hydroxypterostilbene Ameliorated Nonalcoholic Fatty Liver Disease Through Synergistic Modulation of the Gut Microbiota and SIRT1/AMPK Signaling Pathway.

Nonalcoholic fatty liver disease is a common chronic liver disease in many developed countries and is closely linked to metabolic syndrome, obesity, and insulin resistance. In C57BL/6J mice, the present study was conducted to investigate the effects of pterostilbene and its derivative 3'-hydroxypterostilbene on free fatty acids -induced lipid accumulation in HepG2 cells and high-fat diet-induced NAFLD. Pt and OHPt significantly improved FFA-induced steatosis in HepG2 cells and elevated lipolysis by the upregulation of SIRT1/AMPK and insulin signaling pathways, according to the study. Pt and OHPt upregulated the SIRT1/AMPK pathway and then downregulated SREBP-1's protein expression to induce fatty acid oxidation, hindering FA synthesis, according to the results. In the HFD-fed mice, the insulin signaling pathway was stimulated by the insulin signaling pathway, which also improved the insulin resistance and liver function.

Source link: https://europepmc.org/article/MED/35416649


Non-alcoholic Fatty Liver Disease prevalence in Latin America: A systematic review and meta-analysis.

High morbidity and mortality rates are observed among non-alcoholic fatty liver disease patients. In the adult population of Los Angeles, we wanted to determine the prevalence of NAFLD. Keywords related to the NAFLD and LA countries were used. Participants were included in observational studies in adults who were born and live in Los Angeles. Type 2 diabetes mellitus or obesity sufferers had a higher mean prevalence of 68% in comparison to 68%. About 24% in LA, according to We found that the typical incidence of NAFLD in LA is around 24%. For a realistic estimate of the prevalence of NAFLD in Los Angeles, additional studies in the general population using appropriate designs are required.

Source link: https://europepmc.org/article/MED/35427804

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions